Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aditxt Inc. (ADTX:NASDAQ), powered by AI.
Aditxt Inc. is currently trading at $0.14. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aditxt Inc. on Alpha Lenz.
Aditxt Inc.'s P/E ratio is -0.0.
“Aditxt Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -276.4%.”
Ask for details →Aditxt Inc. is a biotechnology company focused on developing technologies that improve the health of the immune system. Its primary purpose is to enhance immune monitoring and reprogramming techniques, which are pivotal in managing diseases and improving the quality of life. The company is involved in creating innovative solutions that can help prevent and treat allergies, viruses, and a variety of immune system-related conditions. Aditxt’s research and technology have significant implications across several sectors, notably in the fields of personalized medicine and infectious diseases. By emphasizing a deeper understanding of the immune system and its dynamics, Aditxt aims to revolutionize approaches to both immune monitoring and therapeutic intervention. In the biotechnology and healthcare markets, its advancements contribute to the growing demand for personalized and precise medical treatments, showcasing its pivotal role in the next generation of medical biotechnology.
“Aditxt Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -276.4%.”
Ask for details →Aditxt Inc. (ticker: ADTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 26 employees. Market cap is $18,155.
The current price is $0.14 with a P/E ratio of -0x and P/B of 0x.
ROE is -276.39% and operating margin is -20796.13%. Annual revenue is $133,985.